Home Categories API Afatinib
A3906656

Afatinib , 98% , 439081-18-2

CAS NO.:439081-18-2

Empirical Formula: C24H25ClFN5O3

Molecular Weight: 485.94

MDL number: MFCD12407405

EINECS: 1308068-626-2

Pack Size Price Stock Quantity
50mg RMB79.20 In Stock
250mg RMB319.20 In Stock
1g RMB1119.20 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Boiling point: 676.9±55.0 °C(Predicted)
Density  1.380
storage temp.  Store at -20°C
solubility  ≥24.3 mg/mL in DMSO; insoluble in H2O; ≥42.1 mg/mL in EtOH with ultrasonic
form  solid
pka 12.06±0.43(Predicted)
color  White to off-white
CAS DataBase Reference 439081-18-2

Description and Uses

In July 2013, the US FDA approved afatinib (also referred to as BIBW- 2992), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) and with tumors that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution. Afatinib functions as an irreversible inhibitor by covalently binding directly to the ATP-binding site in the kinase domains of both EGFR(Cys 773) andHER2 (Cys 805;HER-2 is the preferred dimerization partner of EGFR) resulting in downregulation of EGFR signaling. Afatinib is a potent inhibitor of wild-type and mutant forms (L858R) of EGFR (IC50s of 0.5 and 0.4 nM, respectively), and HER2 (IC50=14 nM), but about 100-fold more active against the gefitinib resistant L858R– T790M EGFR double mutant, with an IC50 of 10 nM. Consistent with its in vitro activity, afatinib induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. A synthetic route to afatinib that employs the displacement of a phenylsulfonyl group to install the (S)-3-hydoxytetrahydrofuran ring and a modified Horner–Wadsworth–Emmons reaction with {[4-(3-chloro-4- phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-ylcarbamoyl]- methyl}-phosphonate and dimethylaminoacetaldehyde-hydrogen sulfite adduct to install the eneamide moiety, has been reported.

BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
HS Code  29349990

RELATED PRODUCTS